CNP-106 not checked
COUR Pharmaceutical Development Company, Inc.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).”In the company’s words, NCT06106672 on ClinicalTrials.gov
- Tested for
- Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
- Main trialPhase 1/2
- “Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.”In the company’s words, NCT06106672 on ClinicalTrials.gov
Other drugs for Myasthenia Gravis
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
- B007Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- Descartes-08Cartesian Therapeutics · Phase 3
- TelitaciceptRemeGen · Phase 3
- Efgartigimodargenx · Phase 3
- TelitaciceptVor Biopharma · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Jun 2026 | Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026